Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 29, 2016. The report serves as a notification of transactions involving Directors and Persons Discharging Managerial Responsibilities (PDMRs) under the GlaxoSmithKline US Deferred Performance Share Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory notification of specific share transactions rather than a financial performance report.
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document details the acquisition of American Depositary Shares (ADSs) by specific executives following a dividend reinvestment.
Management Commentary and Unusual Items
The filing discloses that on April 28, 2016, the Plan Administrators notified the Company of ADS acquisitions by the following individuals at a price of $42.64 per ADS, resulting from the reinvestment of dividends paid on April 14, 2016:
- Dr M M Slaoui: Acquired 619.601 ADSs
- Mr D E Troy: Acquired 833.603 ADSs
This transaction was notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).
Investor Verification Checklist
- Verify the dividend reinvestment price of $42.64 per ADS against market data for April 2016.
- Confirm the total number of ADSs acquired by Dr M M Slaoui and Mr D E Troy.
- Review the full terms of the GlaxoSmithKline US Deferred Performance Share Plan to understand the reinvestment mechanism.
- Note that this filing contains no financial performance data; refer to the company's Form 20-F or quarterly earnings releases for financial metrics.